WALTHAM, MA • 2021-11-30

BostonGene Named One of Massachusetts Best Genetics and Bioinformatics Startups

5 min to read

Criteria for Recognition Includes Exceptional Performance in Innovation, Growth, Management or Societal Impact
BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, announced today that BestStartup.us had named BostonGene a top Massachusetts startup in two categories, “Genetics” and “Bioinformatics."

BestStartup.us evaluated companies on various criteria, including innovation, growth, management, or societal impact. BestStartup.us aims to highlight companies promoting innovative products and breakthrough ideas across the United States.

BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to advance the standard of care, accelerate research, and improve economics. The BostonGene Tumor Portrait Test™, based on integrated genomic and transcriptomic analysis, propels precision medicine into daily clinical practice and supports physicians in actualizing personalized therapy for cancer patients. BostonGene collaborates with many of the leading cancer centers across the United States for research and clinical adoption.

“We are honored to receive this recognition from BestStartup.us,” said Erin O’Reilly, Senior Director, Marketing at BostonGene. “The acknowledgment validates our ongoing commitment to identify novel and personalized treatment options through next-generation multi-platform analytics, further advancing and optimizing outcomes for each cancer patient.”

About BostonGene Corporation

BostonGene is a company at the intersection of technology and biology, dedicated to advancing and personalizing cancer medicine. Founded in 2015, BostonGene has continually pushed the boundaries of innovation to improve cancer patient care and accelerate research and drug development through cutting-edge solutions. Leveraging our AI-powered multiomics platform, we digitize and comprehensively analyze the molecular profiles of cancer patients, including the immune system and tumor microenvironment. Our software solutions, indication-specific cancer library and advanced bioanalytics, enable us to discover multiparametric signatures, identify targets, match them to relevant indications for biopharma and recommend the most effective treatments for patients. For more information, visit www.BostonGene.com.

Erin Keleher O'Reilly

Senior Director